NASDAQ:BNTC Benitec Biopharma (BNTC) Stock Price, News & Analysis $9.59 -0.05 (-0.52%) Closing price 09/25/2026 04:00 PM EasternExtended Trading$9.50 -0.09 (-0.98%) As of 09/25/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Benitec Biopharma Stock (NASDAQ:BNTC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Benitec Biopharma alerts:Sign Up Key Stats Today's Range$9.31▼$9.8050-Day Range$9.59▼$13.7852-Week Range$9.26▼$16.76Volume106,966 shsAverage Volume148,570 shsMarket Capitalization$334.50 millionP/E RatioN/ADividend YieldN/APrice Target$24.00Consensus RatingModerate Buy Company Overview Benitec Biopharma Inc. (NASDAQ:BNTC) is a clinical-stage biotechnology company developing genetic medicines based on DNA-directed RNA interference (ddRNAi). The company’s technology is designed to enable long-lasting suppression of disease-causing genes by delivering genetic instructions that produce RNA interference molecules within targeted cells. Benitec’s lead product candidate is BB-301, an investigational gene therapy being developed for oculopharyngeal muscular dystrophy type 1 (OPMD), a rare inherited disorder that can cause progressive weakness of the muscles involved in swallowing and eye movement. BB-301 uses an adeno-associated virus vector to deliver a ddRNAi construct intended to reduce production of the mutant protein associated with OPMD. Benitec traces its origins to Australia, where the company was founded to develop RNA interference therapies, and it now operates as a U.S.-based biotechnology company. Its development activities are focused primarily on advancing BB-301 and its broader ddRNAi platform through clinical and regulatory development.AI Generated. May Contain Errors. Read More Benitec Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks40th Percentile Overall ScoreBNTC MarketRank™: Benitec Biopharma scored higher than 40% of companies evaluated by MarketBeat, and ranked 669th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingModerate Buy Consensus RatingBenitec Biopharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 7 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialBenitec Biopharma has a consensus price target of $24.00, representing about 150.3% upside from its current price of $9.59.Amount of Analyst CoverageBenitec Biopharma has only been the subject of 4 research reports in the past 90 days.Read more about Benitec Biopharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Benitec Biopharma are expected to decrease in the coming year, from ($1.29) to ($1.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Benitec Biopharma is -9.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Benitec Biopharma is -9.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBenitec Biopharma has a P/B Ratio of 1.86. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Benitec Biopharma's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.58% of the float of Benitec Biopharma has been sold short.Short Interest Ratio / Days to CoverBenitec Biopharma has a short interest ratio ("days to cover") of 19.97, which indicates bearish sentiment.Change versus previous monthShort interest in Benitec Biopharma has recently decreased by 1.28%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBenitec Biopharma does not currently pay a dividend.Dividend GrowthBenitec Biopharma does not have a long track record of dividend growth. News and Social Media2.0 / 5News Sentiment0.20 News SentimentBenitec Biopharma has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Benitec Biopharma this week, compared to 3 articles on an average week.Search Interest2 people have searched for BNTC on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Benitec Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders4.80% of the stock of Benitec Biopharma is held by insiders.Percentage Held by Institutions52.19% of the stock of Benitec Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Benitec Biopharma's insider trading history. Receive BNTC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Benitec Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BNTC Stock News HeadlinesBenitec Biopharma (BNTC) to Announce Earnings on MondaySeptember 21, 2026 | americanbankingnews.comBenitec Biopharma (NASDAQ:BNTC) Stock Rating Lowered by Wall Street ZenSeptember 19, 2026 | americanbankingnews.comReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.September 27 at 1:00 AM | Base Camp Trading (Ad)Analysts Offer Insights on Healthcare Companies: Benitec Biopharma (BNTC), CVS Health (CVS) and BioNTech SE (BNTX)September 16, 2026 | theglobeandmail.comBenitec Biopharma Limited (NASDAQ:BNTC) Receives Average Recommendation of "Moderate Buy" from BrokeragesSeptember 16, 2026 | americanbankingnews.comWedbush Lifts Price Target on Benitec Biopharma to $17 From $16, Keeps Outperform RatingSeptember 15, 2026 | finance.yahoo.comBenitec Biopharma Files $200 Million Shelf RegistrationSeptember 15, 2026 | finance.yahoo.comBenitec Biopharma FY26 Net Loss Widens; BB-301 Interim Data Due In OctoberSeptember 15, 2026 | rttnews.comSee More Headlines BNTC Stock Analysis - Frequently Asked Questions How have BNTC shares performed this year? Benitec Biopharma's stock was trading at $13.47 on January 1st, 2026. Since then, BNTC shares have decreased by 28.8% and is now trading at $9.59. How were Benitec Biopharma's earnings last quarter? Benitec Biopharma Limited (NASDAQ:BNTC) announced its quarterly earnings data on Monday, September, 14th. The biotechnology company reported ($0.26) earnings per share for the quarter, topping analysts' consensus estimates of ($0.26) by $0.00. When did Benitec Biopharma's stock split? Shares of Benitec Biopharma reverse split on Wednesday, July 26th 2023.The 1-17 reverse split was announced on Wednesday, July 26th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 26th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. When did Benitec Biopharma IPO? Benitec Biopharma (BNTC) raised $0 in an initial public offering on Thursday, August 6th 2015. The company issued 0 shares at $0.00 per share. BMO Capital Markets and Maxim Group LLC served as the underwriters for the IPO and Roth Capital Partners was co-manager. Who are Benitec Biopharma's major shareholders? Top institutional shareholders of Benitec Biopharma include AWM Investment Company Inc. (0.55%), Bank of New York Mellon Corp (0.17%), GAMMA Investing LLC (0.02%) and California State Teachers Retirement System. View institutional ownership trends. How do I buy shares of Benitec Biopharma? Shares of BNTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Benitec Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Benitec Biopharma investors own include Amarin (AMRN), Pfizer (PFE), ADMA Biologics (ADMA), BioLineRx (BLRX), Exelixis (EXEL) and Sorrento Therapeutics (SRNE). Company Calendar Last Earnings9/14/2026Today9/27/2026Next Earnings (Estimated)9/28/2026Fiscal Year End6/30/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 For the last 9 days, BNTC's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:BNTC CIK1808898 Webwww.benitec.com Phone510-780-0819Fax61 (0)3 9966-9923Employees19Year Founded2001Price Target and Rating Average Price Target for Benitec Biopharma$24.00 High Price Target$32.00 Low Price Target$17.00 Potential Upside/Downside+150.3%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($0.98) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$45.55 million Net MarginsN/A Pretax MarginN/A Return on Equity-28.41% Return on Assets-27.76% Debt Debt-to-Equity RatioN/A Current Ratio34.00 Quick Ratio34.00 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.15 per share Price / Book1.86Miscellaneous Outstanding Shares34,880,000Free Float33,209,000Market Cap$334.50 million OptionableNo Data Beta0.27 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:BNTC) was last updated on 9/27/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | Sponsored100% overnight gains?Rumors are circulating that Elon Musk is preparing to acquire three publicly traded companies. Dr. Mark Sko...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Benitec Biopharma Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Benitec Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
